FGAM
PTGX icon

Financial Gravity Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Financial Gravity Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18
Closed -$522 – 2188
2024
Q1 		$522 Buy
+18
New +$490 ﹤0.01% 1364
2023
Q3 		– Sell
-28
Closed -$470 – 1645
2023
Q2 		$470 Buy
+28
New +$701 ﹤0.01% 1012
2023
Q1 		– Sell
-11
Closed -$197 – 1533
2022
Q4 		$197 Buy
+11
New +$93 ﹤0.01% 950
2020
Q1 		– Sell
-55
Closed -$7K – 1302
2019
Q4 		$7K Hold
55
– – ﹤0.01% 1237
2019
Q3 		$1K Hold
55
– – ﹤0.01% 1092
2019
Q2 		$1K Hold
55
– – ﹤0.01% 1116
2019
Q1 		$1K Buy
+55
New +$485 ﹤0.01% 1166
2018
Q3 		$0 Hold
55
– – ﹤0.01% 1572
2018
Q2 		$1K Buy
55
+53
+2,650% +$407 ﹤0.01% 1242
2018
Q1 		$0 Buy
+2
New +$38 ﹤0.01% 1483

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Financial Gravity Asset Management's PTGX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 18 shares — an estimated $522 sold.

Financial Gravity Asset Management first reported a position in PTGX in Q1 2018 and held it in 10 quarters. The position peaked at $7K in Q4 2019. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 18 Protagonist Therapeutics shares in Q2 2024, an estimated $522.
  • Financial Gravity Asset Management first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 10 quarters.
  • Financial Gravity Asset Management's Protagonist Therapeutics position peaked at $7K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.